TP53 and skin cancer: To establish a platform to investigate the effects of calcipotriol-plus–5-FU immunotherapy on skin cancer precursors in vivo, we examined the efficacy of calcipotriol-plus–5-FU immunotherapy in controlling mutant p53 clones in the DMBA-plus–ultraviolet radiation (DMBA-plus–UVB) skin carcinogenesis model (51).